The therapeutic application of Корвалмент (Corvalment) is focused on providing supportive symptomatic relief in contexts defined by symptoms related to heightened physiological activity and functional cardiovascular discomfort. The core compound's role as a sedative is established through its active component, Menthyl Isovalerate.

Relief from Nervous and Functional Discomfort

The medicine is commonly used across domains where short-term symptomatic assistance is needed during phases of emotional or physiological overload. It is considered relevant for easing symptoms of heightened nervous tension, generalized irritability, unease associated with mild neurotic states, functional cardiovascular discomfort, cardialgia, and mild attacks of angioneurotic angina. These manifestations are generally linked to a nervous or emotional component.

“The primary benefit contributes to a calming and soothing effect, helping patients cope more steadily with symptom fluctuations during periods of increased distress.”

The medicine is often applied in scenarios where additional management of discomfort is required when these symptoms intensify, and supports the patient to address disruptive manifestations and contribute to improved day-to-day comfort.

---

Quick Fact: Relief for Nervous and Functional Discomfort
Main Use: Symptomatic relief for functional symptoms of nervous tension and cardialgia.
Context: Applied when short-term symptomatic assistance is needed for episodic discomfort.
Benefit: May assist with general well-being during periods of heightened symptoms.

Regulatory References

1. menthyl isovalerate - WHO | JECFA

The official regulatory profile for Корвалмент (Menthyl isovalerate) strictly defines eligible and non-eligible patient populations. Eligibility is granted only to adults who do not exhibit any official contraindications.

Populations Excluded from Use

Classification	Population/Condition
Contraindicated	Individuals with known hypersensitivity to menthyl isovalerate or any product component.
Contraindicated	Patients experiencing Acute Myocardial Infarction (AMI).
Contraindicated	Patients with Severe Arterial Hypotension (very low blood pressure).

Populations with Restricted or Non-Recommended Use

Official labels indicate caution or exclusion for certain groups due to safety concerns or insufficient data:

• Age Restriction: Use is officially not recommended or contraindicated for children and adolescents under 18 years of age.
• Reproductive Status: The medicine is not recommended or contraindicated for use by women who are pregnant or breastfeeding.
• Comorbid Conditions: Caution is required for patients with Diabetes Mellitus (due to excipients in the formulation).

Regulatory documentation establishes that individuals must be 18 or older, have no component sensitivity, and be free from severe cardiovascular events (AMI, Severe Hypotension) to be considered eligible for use.

Interactions with other medicines and products

Category	Interaction Pattern
Pharmacodynamic Potentiation	Additive sedative effects; additive antihypertensive effects.
Effect Modification	Potential for heightened effects with blood pressure lowering agents.
Contraindications	None explicitly listed as a drug-drug interaction prohibition in regulatory documents.

Official Interaction Statements:

Regulatory documentation defines the product's interaction profile primarily through pharmacodynamic potentiation with various substance classes. Co-administration with psychotropic agents, opioid analgesics, or anesthetic agents is formally documented to enhance the sedative effect. Similarly, simultaneous use with antihypertensive medicinal products may potentiate their action, increasing the resulting effect of blood pressure reduction.

An additive sedative effect is also officially documented to occur with the consumption of alcohol (ethanol). Furthermore, the official profile includes a specific mitigating interaction: the medicine is documented to reduce the severity of headache caused by the use of nitrates.

Interaction Constraints and Classification:

These interactions are classified as combinations that carry a risk of potentiation and require consideration upon simultaneous use. No specific pharmacokinetic (CYP or transporter) interactions are documented, nor are any mandatory dose separation or timing rules listed in the official prescribing information.

Корвалмент is composed primarily of menthyl isovalerate, a menthyl ester. The mechanism is attributed to its constituent, menthol, which targets the peripheral nervous and cardiovascular systems.

Menthol acts as an agonist at Transient Receptor Potential Melastatin 8 (TRPM8) channels, a class of non-selective cation channels expressed in sensory neurons and vascular cells, including the endothelium and smooth muscle.

Activation of neuronal TRPM8 channels on peripheral sensory C-fibers generates a neural signal perceived at the level of the central nervous system. Activation of endothelial TRPM8 channels initiates an increase in intracellular calcium concentration. This rise in calcium activates endothelial nitric oxide synthase (eNOS), leading to increased synthesis and release of nitric oxide (NO). NO then diffuses to adjacent vascular smooth muscle cells, stimulating soluble guanylate cyclase (sGC) and increasing the concentration of cyclic guanosine monophosphate (cGMP). This downstream cascade results in dephosphorylation of the myosin light chain, triggering vasorelaxation and a subsequent increase in blood flow in localized vascular territories.

Administration Guidelines

Корвалмент is formulated as a 100 mg solution of menthol in menthyl isovalerate, contained within soft gelatin capsules. The method of administration is sublingual, requiring the capsule to be held under the tongue until its complete dissolution.

---

Instruction Map: How to use Корвалмент

Instruction Entity	Detail
Route of administration	Sublingual (under the tongue).
Dosing schedule	Single Dose: 1 capsule (100 mg). Maximum Daily Dose: 6 capsules (600 mg).
Timing in relation to meals	Administration is independent of food intake.
Preparation requirements	Capsule must be held under the tongue until complete dissolution. May be crushed or bitten with the teeth to accelerate the effect.
Age-group administration rules	Dosing is for adults. The preparation is suitable for use in patients with diabetes mellitus, as it is sugar-free.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Sublingual.
Frequency pattern	As-needed (Symptom-Contingent use). Typically 2–3 times per day.
Use-context constraints	Short-term symptomatic use, with treatment duration limited to up to 7 days.

---

Resulting Procedural Structure

The medicine is designed for use upon the onset of symptoms. The procedure involves a single 100 mg capsule being administered sublingually and allowed to dissolve fully. To ensure proper use, the total intake must not exceed 6 capsules (600 mg) over 24 hours. The guidelines further establish a procedural limit, requiring medical consultation for alternative therapy if the expected therapeutic effect is absent or insufficient within 5–10 minutes of administration.

Research Evidence / Overview of Studies for Корвалмент

Evidence for Use in Nervous Tension and Irritability

Research exploring the use of Корвалмент for nervous tension and generalized irritability was studied for its properties associated with sedation and calming. These investigations primarily included pharmacological studies that examined the Menthyl Isovalerate component and was observed for its relationship to the central nervous system. The evidence base also includes older, localized clinical observations and reports applied in studies examining patient-reported experiences of tension. The study designs evaluated subjective changes reported on anxiety or tension scales, alongside physiological measures of the autonomic nervous system.

Clinical observations reported patterns related to measured outcomes describing perceived discomfort following acute administration. Research describes changes monitored in the body’s stress index and other physiological markers during the study period. This evidence contributes to understanding symptom patterns in conditions characterized by fluctuating or episodic manifestations of nervous discomfort.

Evidence for Use in Functional Cardiovascular Discomfort (Cardialgia)

This section will describe the research background, including pharmacological data on the components and the types of clinical observations used to assess the medicine’s use in functional heart discomfort. The clinical research included studies of adults presenting with functional cardiac discomfort, often involving older, local clinical observations and observational settings evaluating daily-life functioning.

Clinical trials described the measurement of changes in subjective ratings of chest discomfort in the acute phase after administration. Data show patterns related to the speed of onset for episodic symptoms measured in acute-use contexts. Findings reported were derived primarily from regional or localized clinical environments. This evidence provides insight into short-term changes in outcomes describing episodic or acute changes.

Unanswered Questions and Research Gaps

Scientific literature and regulatory overviews point to several significant gaps in the research for Корвалмент. The most notable limitation is the lack of modern, large-scale randomized controlled trials (RCTs). This means that comparative evidence against non-treatment (placebo) or standard care is lacking, making it difficult to precisely gauge the magnitude of observed patterns.

The historical and localized nature of the studies means that evidence quality varies across studies, contributing to the fact that certainty remains low. Research provides context but not individual predictions. As long-term effects are not fully established, more research is needed to explore the outcomes of repeated or sustained use.

Key Studies & References

1. Menthyl isovalerate (Validol) - WHO | JECFA Food Additives Database

Common questions about Корвалмент (FAQ)

Q: How long do the effects of Корвалмент usually last?

The medicine is generally administered as-needed for symptomatic relief, with a documented frequency limit in a 24-hour period. This usage pattern implies the effect is sufficient to provide relief between periods of administration. However, the official product information does not specify the exact duration of the effect in hours.

Q: Can Корвалмент be taken for sleep difficulties?

The official uses for this medicine are related to the relief of nervous tension (neuroses) and functional heart discomfort (cardialgia). While the product is classified as a sedative agent, its regulatory indications do not specifically include the treatment of primary sleep disorders, such as chronic insomnia.

Q: What are the most common side effects people report with Корвалмент?

Regulatory documents list documented adverse effects, but they typically do not provide specific numerical frequencies to label effects as 'most common' in consumer information. Known side effects described in official labeling include reactions such as nausea, dizziness, skin rash, and a potential for hypotension (low blood pressure).

Q: Is it common to feel a slight coolness in the mouth after taking Корвалмент?

A sensation of coolness in the mouth may be experienced. This effect is related to the presence of Levomenthol, one of the active ingredients. Official sources state that Levomenthol is known to locally affect nerve endings, which can create a cool sensation upon administration.

Q: Does taking Корвалмент make you feel drowsy?

As the product is classified as a sedative agent, it may potentially cause reduced alertness. Official product information also lists dizziness as a possible side effect, which is related to sedation. This potential effect is noted in the official profile.

Q: Can older adults (seniors) safely use Корвалмент?

The medicine is generally intended for use by adults. Official safety documentation notes that it is contraindicated (should not be used) in cases of severe arterial hypotension (very low blood pressure). Older adults may be more susceptible to the hypotensive and sedative effects noted in regulatory documentation.

Q: Does Корвалмент interact with any common herbal supplements?

Regulatory documents do not explicitly list interactions with specific herbal supplements. However, official regulatory information notes the risk of potentiation (enhancement) when combined with substances that have similar sedative or blood pressure-lowering properties.

Q: What happens if a person accidentally takes too many capsules?

Taking excessive doses may lead to signs of overdose. According to regulatory documentation, these symptoms may include nausea, a significant drop in blood pressure (hypotension), and effects on the central nervous system. Treatment involves discontinuing the medicine, and management is based on the symptoms observed.

Q: Does Корвалмент affect driving ability?

Due to its sedative properties and the potential side effect of dizziness, caution is officially advised. The official warnings regarding operating vehicles or machinery are tied to the risk of side effects that could impair attention or coordination.

Q: What is the shelf life of Корвалмент capsules?

The official regulatory documents specify the shelf life for the product. This shelf life is typically two years from the date of manufacture, provided the capsules are stored correctly as directed in the packaging instructions.

Q: Is there a different dosage form of Корвалмент available besides capsules?

The specific drug is manufactured and marketed as an oil solution in soft gelatin capsules intended for sublingual (under-the-tongue) use. Official regulatory records do not generally list other specific dosage forms marketed under this product name.

Q: Why do official sources list validol as an equivalent name?

Official records reflect that both Корвалмент and Validol are proprietary names for the same core active substance: menthyl isovalerate. This equivalence is noted in regulatory documents and reflects the historical use of this substance as a sedative and cardiological agent in its region of origin.

Q: Is the effect of Корвалмент psychological or purely physiological?

Official pharmacological descriptions indicate that the medicine has both physiological and sedative actions. Its effect involves a reflex vasodilating effect (widening of blood vessels, which is physiological) and a direct sedative effect on the central nervous system, leading to a feeling of calm.

Q: Is Корвалмент safe for people with liver or kidney issues (informational)?

Official regulatory documents do not typically specify contraindications or require major dose adjustments for patients with liver or kidney impairment in the context of this medicine. The general safety profile does not include specific warnings regarding these conditions.

Q: Why is Korvalment often mentioned in discussions about motion sickness?

Official indications for the drug, or its active substance Validol, include its use as an antiemetic to help relieve symptoms associated with sea and air sickness (motion sickness). This is an established use context documented in some regulatory regions.

Q: Are there different versions or strengths of Корвалмент?

The standard marketed strength for the Корвалмент capsules is 100 mg per single capsule. Regulatory documents do not list other strengths marketed under this specific product name.

Q: What should I do if I miss a dose of Корвалмент?

Since the medicine is officially indicated for symptom-contingent (as-needed) use, there is no fixed dosing schedule to follow, and a 'missed dose' protocol is not applicable. When symptoms recur, a capsule may be taken, ensuring the total daily limit is not exceeded.

Q: Does Корвалмент help specifically with heart palpitations?

Official documentation states the drug is used for relief of general functional cardiovascular discomfort. While palpitations are a form of functional discomfort, official product information does not specifically confirm 'palpitations' as a dedicated treated symptom. The core section on uses describes its primary indications.

Q: Why do some people confuse Корвалмент with nitroglycerin?

Some potential for confusion exists because regulatory information notes that this medicine has a vasodilator property, a mechanism also found in drugs like nitroglycerin. Additionally, the official interaction profile states that the medicine can reduce the severity of headaches caused by nitrates (the class of drugs nitroglycerin belongs to).

How to Store and Dispose of Korvalment?

The official regulatory labeling defines specific conditions for storing Korvalment (Menthyl isovalerate) to ensure the stability and integrity of the soft gelatin capsules.

---

Storage Conditions

Requirement	Description
Temperature Limit	Store at a temperature not exceeding 25 C (77 F).
Protection	The medicine must be protected from moisture and kept in the original packaging.
Child Safety	It is required to keep Korvalment out of the sight and reach of children.

---

Disposal Instructions

Specific disposal instructions are not detailed beyond general requirements. Unused, unwanted, or expired Korvalment must be disposed of according to local laws and regulations for pharmaceutical waste.